Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer

J Int Med Res. 2003 Nov-Dec;31(6):469-74. doi: 10.1177/147323000303100601.

Abstract

This study compared the efficacy of an H2-receptor antagonist (H2RA)- and a proton-pump inhibitor (PPI)-based triple regimen for the eradication of Helicobacter pylori infection. Chinese patients with H. pylori-associated gastritis or peptic ulcer were randomized to receive the H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin and 0.4 g metronidazole) or the PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin and 0.4 g metronidazole) both twice daily for 1 or 2 weeks. Successful eradication of H. pylori was determined by the 13C-urea breath test and gastric mucosa histology at least 4 weeks after completion of antibiotic therapy. Eradication rates were 56.0% and 76.9% for the 1-week H2RA- and PPI-based triple regimens, respectively, and 81.6% and 82.1% for the 2-week regimens, respectively. The H. pylori eradication rate for the 2-week H2RA regimen was significantly higher than that for the 1-week regimen, but there were no significant differences between the 1- and 2-week PPI regimens. The two regimens proved equally effective in eradicating H. pylori infection.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amoxicillin / therapeutic use
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / therapeutic use
  • China
  • Drug Therapy, Combination
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology*
  • Famotidine / therapeutic use*
  • Female
  • Gastritis / drug therapy*
  • Gastritis / microbiology
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / pathogenicity
  • Histamine H2 Antagonists / adverse effects
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / therapeutic use
  • Pain / drug therapy
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / microbiology
  • Proton Pump Inhibitors
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Enzyme Inhibitors
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors
  • Metronidazole
  • Famotidine
  • Amoxicillin
  • Omeprazole